Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Nelfinavir · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| Nelfinavir mesylate | DRUG | - |
| Stavudine | DRUG | - |
| Didanosine | DRUG | - |
Inclusion Criteria You may be eligible for this study if you: * Are HIV-positive. * Are at least 18 years old. * Have a viral load of at least 5,000 copies/ml and a CD4 count of at least 100 cells/mm3. Exclusion Criteria You will not be eligible for this study if you: * Have received more than ...
Top 20 of 28 competitors
Nelfinavir is used for the treatment of HIV infections. It is a small molecule drug being developed by Bristol-Myers Squibb Company for this infectious disease indication.
Nelfinavir is an antiretroviral drug that works by inhibiting the HIV protease enzyme, which is essential for the virus to replicate. By blocking this enzyme, Nelfinavir prevents the virus from maturing and producing infectious particles.
Nelfinavir is developed by Bristol-Myers Squibb Company, which is listed on the stock exchange under the ticker BMY.
Nelfinavir is in Phase 3 clinical development. It is an investigational drug and has not been approved by regulatory authorities for the treatment of HIV infections.
Nelfinavir has been studied in one completed Phase 3 clinical trial with the identifier NCT00002224. This trial compared two anti-HIV regimens that included one of two forms of didanosine (ddI) in 120 participants with HIV infections in the United States and Canada.
Nelfinavir is also known by the brand name Viracept. It is the same drug, and both names refer to the HIV protease inhibitor developed by Bristol-Myers Squibb.